Abstract

Biocryst Pharmaceuticals will report first-quarter 2026 results on May 6, 2026 Pre-Market, with investor attention centered on revenue growth durability from the core franchise, margin trajectory following last quarter’s step-up, and how 2026 guidance aligns with latest prescription trends.

Market Forecast

For the March quarter, current estimates point to revenue of 151.12 million US dollars, up 19.12% year over year, EBIT of 20.44 million US dollars, up 137.67% year over year, and adjusted EPS of 0.05, up 171.24% year over year. Margin guidance for the quarter has not been specified; the last reported quarter featured an 88.11% gross margin and a 60.47% net profit margin that serve as the latest reference points for the margin structure, though these levels are expected to normalize as license revenue steps down.

The main business remains anchored by the oral prophylactic therapy that continues to add patients, with management previously reaffirming full-year 2026 total revenue targets, and the cadence of new starts plus payer dynamics setting the tone for near-term revenue quality. The most promising contributor is the flagship product franchise, which generated 601.80 million US dollars in 2025, up 38.00% year over year, supported by continued penetration and broader patient access initiatives.

Last Quarter Review

In the prior quarter, Biocryst Pharmaceuticals delivered revenue of 162.58 million US dollars, up 23.60% year over year, a gross profit margin of 88.11%, GAAP net profit attributable to shareholders of 246.00 million US dollars, a net profit margin of 60.47%, and adjusted EPS of 0.01, up 107.69% year over year.

A key financial highlight was the substantial contribution recognized from licensing activity associated with the European transaction, which, coupled with disciplined operating spend, supported profitability and deleveraging. On the operating side, product revenue continued to expand, with quarterly revenue of 162.58 million US dollars up 23.60% year over year, demonstrating persistent demand and favorable prescription trends in the core therapy, while the company’s business mix reflected strong product momentum, complemented by license and collaboration streams.

Current Quarter Outlook

Core Product Franchise

The core franchise is expected to remain the principal engine of growth in the March quarter. Patient starts, adherence, and modest net price tailwinds are the primary levers, and current estimates for revenue growth of 19.12% year over year imply resilient demand following the robust exit from 2025. Script trajectory observed through the first part of 2026 suggests that the installed base continues to expand, with prescriber breadth holding up well after the seasonal transition into the new plan year. Operationally, the revenue mix will likely revert toward a more typical product-dominant profile now that last quarter’s license-related uplift has passed, which should lower reported net margin versus the prior print while still supporting solid EBIT growth given the 137.67% year-over-year estimate for the quarter.

The gross margin framework remains favorable for an oral therapy, as reflected in the 88.11% gross margin in the prior quarter, and should remain elevated even as the revenue mix normalizes back toward product sales. Volume growth has historically driven attractive contribution margins, which, together with ongoing discipline on non-GAAP operating expenses, offers a path to expanding operating profit in 2026. In this context, the market will parse whether quarterly revenue lands close to the 151.12 million US dollars estimate and whether operating leverage shows through in the form of improved EBIT flow-through versus the last product-only quarter baseline.

Expansion Catalysts and the Most Promising Business

The most promising near-term expansion driver centers on the core therapy’s lifecycle and access initiatives. In 2025, franchise revenue reached 601.80 million US dollars, up 38.00% year over year, and that momentum remains the benchmark heading into 2026. With the therapy’s pediatric oral pellets approval announced earlier this year, the addressable patient pool is broadening, and this quarter provides the first clean window for early uptake signals. The company’s commercial focus is on seamless onboarding, maintaining strong persistency, and ensuring minimal friction as new prescribers engage, which should help sustain mid-teens to high-teens revenue growth implied by the quarter’s 19.12% year-over-year estimate.

Beyond the core therapy, portfolio expansion from the recently closed transaction adds a second potential pillar within the same disease area. The addition of a late-stage asset deepens the pipeline in prophylaxis and potentially extends the company’s reach across treatment preferences and dosing intervals. While this will not materially affect March-quarter revenue, integration work streams and program milestones guide the narrative for 2H26 and 2027, and any updates to development timelines or regulatory interactions during the earnings call will influence how investors model medium-term growth.

What Will Drive the Stock This Quarter

Share performance around the print will hinge on three elements: revenue quality, margin normalization, and the magnitude of 2026 guidance reiteration. Revenue quality means how much of the quarter’s growth is driven by net new patient adds and persistency versus any non-recurring items; investors are likely to reward a print that delivers close to the 151.12 million US dollars estimate with evidence of ongoing prescription breadth and depth. Margin normalization is equally important: last quarter’s 60.47% net margin was boosted by license revenue, so the market expects a step down; the focus will be on whether gross margins remain structurally high and whether operating expense discipline keeps EBIT near the 20.44 million US dollars estimate. Finally, the degree to which management reiterates or tightens full-year 2026 revenue guidance of the mid-600 million US dollars range will be critical to sustaining confidence in the run-rate exiting the first half.

Cash generation and balance sheet positioning remain supportive. Last year’s proceeds from the European transaction helped retire term debt, and the company enters 2026 with greater financial flexibility to fund both commercial and late-stage development priorities. As capital allocation shifts toward supporting the integrated portfolio and supply chain readiness, investors will look for commentary on the path to consistently positive non-GAAP operating profit and how that translates into cash flow throughout the year. A clear articulation of spend cadence relative to growth should help anchor valuation around forward revenue multiples that assume the core therapy’s durable trajectory.

Analyst Opinions

Bullish views dominate recent coverage, with a clear majority on the positive side (bullish: 4; bearish: 0) over the last six months, and targets generally framed around continued growth of the core franchise and pipeline optionality.

- RBC Capital Markets: Brian Abrahams has reiterated an Outperform/Buy view with a 13.00 US dollars price target in recent updates and has also framed scenario analyses that point to upside across multiple paths. In a broader assessment of potential outcomes, RBC’s base case contemplated valuation support in the mid-teens per share, with an upside case extending above that range, citing the durability of the prophylaxis franchise and incremental contribution from the newly added late-stage asset. Importantly for the current quarter, RBC’s stance implies that a revenue print near the 151.12 million US dollars estimate and a clean demand narrative could be sufficient to sustain positive sentiment even if reported margins normalize from last quarter’s elevated level.

- Wedbush: Laura Chico has maintained an Outperform view and recently edged the target price to 22.00 US dollars. Wedbush’s thesis highlights steady patient adds, the benefit of pediatric availability to expand reach, and disciplined expense management that underpins positive non-GAAP operating profit in 2026. For the upcoming print, the house will likely focus on whether adjusted EPS tracks toward the 0.05 estimate, given the 171.24% year-over-year implied growth, and whether operating leverage shows through in the EBIT figure relative to the 20.44 million US dollars estimate.

- Cantor Fitzgerald: Steven Seedhouse remains positive with a 26.00 US dollars target, emphasizing sustained commercial execution and the multi-year runway for the prophylaxis therapy. Cantor’s framework implies that, as long as quarterly results continue to show high-teens growth with consistent gross margins and steady operating discipline, valuation can compress toward peer medians on forward revenue and EBITDA. That lens suggests this quarter’s key sensitivity lies in the quality of demand indicators, including prescriber breadth, patient retention, and any commentary on payer changes.

- Evercore ISI: Coverage resumed with a Buy and a 17.00 US dollars target, calling out the company’s strengthened balance sheet and the strategic fit of the recent portfolio addition. Evercore’s positive stance for 2026 is predicated on visible revenue drivers in the core therapy and the de-risking from stronger cash and reduced leverage. Translating that to the March-quarter setup, Evercore likely expects a revenue print in line with the 151.12 million US dollars estimate and looks for management to reiterate full-year revenue targets; any incremental color on pipeline timelines could serve as a secondary catalyst.

Synthesis of the bullish majority points to a consistent narrative: the demand arc for the core therapy remains intact, pediatric availability adds to the growth layers, and operating discipline should sustain improving profitability metrics through 2026 even as quarter-to-quarter margins ebb with mix. The implicit hurdle for the March quarter is not a blowout relative to consensus, but rather a clean, in-line revenue and EPS print with corroborating demand details that backstop the 2026 revenue framework. Should management pair an in-line quarter with firm guidance and constructive qualitative commentary on early pediatric uptake and portfolio integration, the bullish case sees limited downside to estimates and room for modest upward revisions later in the year.

In practical terms, the bullish camp will scrutinize four datapoints on May 6, 2026: revenue near 151.12 million US dollars, adjusted EPS near 0.05, confirmation that operating expenses track to plan, and reiteration of the full-year revenue guide in the 635–660 million US dollars range. Positive alignment on these markers would likely keep the shares supported in the near term, while any early proof points in pediatric uptake or clear milestones for the late-stage asset could widen the path for multiple expansion. Conversely, if revenue softness were to appear without offsetting commentary on forthcoming catalysts or cost control, the bullish view would shift to a wait for second-quarter validation, but the prevailing opinion anticipates sufficient traction to maintain constructive estimates.